Abstract | AIMS: MATERIALS AND METHODS: We studied 9 CKD patients with hyperuricemia, whose mean serum acid concentration was 10.2 (range 8.3-15.8) mg/dl. No study subject was taking allopurinol (3/9 are allopurinol intolerant). Patients were treated with rasburicase (0.2 mg/kg/day) in single dose by intravenous infusion over a 30-min period. Serum samples were collected after 1, 4, 8, 24, 48 and 72 h, after 1 week, and after 1 month. To evaluate the efficacy of rasburicase, plasma and urinary concentrations of uric acid were determined by the standard method; the plasma activity of rasburicase was determined using a new assay developed by our laboratory (chromatography-mass method, a colorimetric 96-well microtiter plate assay). RESULTS: All the treated patients experienced a rapid reduction in their plasma uric acid concentration. Data showed an undetectable value within 1 h of treatment. The rasburicase effect ended after 50 h, with a slow increase in the plasma level of uric acid. CONCLUSION: A single dose of rasburicase is highly effective and well tolerated in the treatment of hyperuricemia in selected CKD patients.
|
Authors | E Sestigiani, M Mandreoli, M Guardigli, A Roda, E Ramazzotti, P Boni, A Santoro |
Journal | Nephron. Clinical practice
(Nephron Clin Pract)
Vol. 108
Issue 4
Pg. c265-71
( 2008)
ISSN: 1660-2110 [Electronic] Switzerland |
PMID | 18418005
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright 2008 S. Karger AG, Basel. |
Chemical References |
- Recombinant Proteins
- rasburicase
- Uric Acid
- Urate Oxidase
|
Topics |
- Adult
- Aged
- Female
- Humans
- Hyperuricemia
(drug therapy, etiology)
- Infusions, Intravenous
- Kidney Failure, Chronic
(complications, metabolism)
- Kidney Function Tests
- Luminescent Measurements
(methods)
- Male
- Middle Aged
- Recombinant Proteins
(administration & dosage, pharmacokinetics)
- Urate Oxidase
(administration & dosage, pharmacokinetics)
- Uric Acid
(blood, metabolism, urine)
|